Health-Related Quality of Life in Patients with Spinocerebellar Ataxia: a Validation Study of the EQ-5D-3L

被引:0
作者
Maresa Buchholz
Niklas Weber
Anika Rädke
Jennifer Faber
Tanja Schmitz-Hübsch
Heike Jacobi
Feng Xie
Thomas Klockgether
Bernhard Michalowsky
机构
[1] Translational Health Care Research,Department of Neurology
[2] German Center for Neurodegenerative Diseases (DZNE),Department of Neurology
[3] Site Rostock/Greifswald,Department of Health Research Methods, Evidence and Impact
[4] German Center for Neurodegenerative Diseases (DZNE),undefined
[5] University Hospital Bonn,undefined
[6] Experimental and Clinical Research Center,undefined
[7] a cooperation of Max-Delbrueck Center of Molecular Medicine and Charité – Universitätsmedizin Berlin,undefined
[8] University Hospital Heidelberg,undefined
[9] McMaster University,undefined
来源
The Cerebellum | 2024年 / 23卷
关键词
Validation; EQ-5D-3L; Health-related quality of life; Spinocerebellar ataxia;
D O I
暂无
中图分类号
学科分类号
摘要
Although health-related quality of life (HRQoL) has developed into a crucial outcome parameter in clinical research, evidence of the EQ-5D-3L validation performance is lacking in patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. The objective of this study is to assess the acceptability, validity, reliability, and responsiveness of the EQ-5D-3L. For n = 842 predominantly European SCA patients of two longitudinal cohort studies, the EQ-5D-3L, PHQ-9 (Patient Health Questionnaire), and ataxia-specific clinical assessments (SARA: Scale for Assessment and Rating of Ataxia; ADL: activities of daily living as part of Friedreich’s Ataxia Rating Scale; INAS: Inventory of Non-Ataxia Signs) were assessed at baseline and multiple annual follow-ups. The EQ-5D-3L was evaluated regarding acceptability, distribution properties, convergent and known-groups validity, test-retest reliability, and effect size measures to analyze health changes. The non-item response was low (EQ-5D-3L index: 0.8%; EQ-VAS: 3.4%). Ceiling effects occurred in 9.9% (EQ-5D-3L) and 3.0% (EQ-VAS) with a mean EQ-5D-3L index of 0.65 ± 0.21. In total, convergent validity showed moderate to strong Spearman’s rho (rs > 0.3) coefficients comparing EQ-5D-3L and EQ-VAS with PHQ-9, SARA, ADL, and INAS. EQ-5D-3L could discriminate between groups of age, SARA, ADL, and INAS. Intra-class correlation coefficients (EQ-5D-3LICC: 0.95/EQ-VASICC: 0.88) and Kappa statistics (range 0.44 to 0.93 for EQ-5D-3L items) indicated tolerable reliability. EQ-5D-3L shows small (effect size < 0.3) to moderate (effect size 0.3–0.59) health changes regarding ataxia severity. The analysis confirms an acceptable, reliable, valid, and responsive recommended EQ-5D-3L in SCA patients, measuring the HRQoL adequately, besides well-established clinical instruments.
引用
收藏
页码:1020 / 1030
页数:10
相关论文
共 182 条
  • [1] Sullivan R(2019)Spinocerebellar ataxia: an update J Neurol 266 533-544
  • [2] Yau WY(2021)Tezenas du Montcel S, Klockgether T. Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis J Neurol 268 2749-2756
  • [3] O'Connor E(2014)The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies Neuroepidemiology. 42 174-183
  • [4] Houlden H(2015)Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study Lancet Neurol 14 1101-1108
  • [5] Diallo A(2022)Quality of life since pre-ataxic phases of spinocerebellar ataxia type 3/Machado-Joseph disease Cerebellum. 21 297-305
  • [6] Jacobi H(2014)Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers PLoS One 9 e110216-292
  • [7] Ruano L(2009)The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov Contemp Clin Trials 30 289-128
  • [8] Melo C(2008)Health related quality of life measures in Friedreich ataxia J Neurol Sci 272 123-2051
  • [9] Silva MC(2018)Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias J Neurol 265 2040-895
  • [10] Coutinho P(2021)Discordance between patient-reported outcomes and physician-rated motor symptom severity in early-to-middle-stage spinocerebellar ataxia type 3 Cerebellum. 20 887-595